Benchmark Downgrades Amedisys (AMED) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Benchmark analyst Bill Sutherland downgraded Amedisys (NASDAQ: AMED) from Buy to Hold.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
Shares of Amedisys closed at $91.00 yesterday.
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- JPMorgan Downgrades Fidelity National Information Services (FIS) to Neutral
- Oppenheimer Downgrades Fidelity National Information Services (FIS) to Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
